Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for EGRX. Our analysts highlight strong fundamentals and favorable market sentiment, positioning EGRX for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: EGRX is a Strong Buy candidate.
EGRX stock price ended at $0.35 on 星期二, after dropping 50.00%
On the latest trading day Jan 27, 2026, the stock price of EGRX fell by 50.00%, dropping from $0.35 to $0.35. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.35 and a high of $0.35. On the latest trading day, the trading volume for EGRX rose by 1.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 2.3K shares were traded, with a market value of approximately $4.5M.